Revance Therapeutics Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Revance Therapeutics stock.
View analyst ratings for Revance Therapeutics or view top-rated stocks.

Wall Street analysts have given Revance Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Revance Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Revance Therapeutics.

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its earnings results on Monday, May, 10th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.19) by $0.11. The biopharmaceutical company earned $13.30 million during the quarter, compared to analysts' expectations of $12.44 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 93.59% and a negative net margin of 1,021.48%.
View Revance Therapeutics' earnings history.

Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RVNC stock has increased by 73.7% and is now trading at $31.21.
View which stocks have been most impacted by COVID-19.

4 brokerages have issued 12 month target prices for Revance Therapeutics' shares. Their forecasts range from $35.00 to $45.00. On average, they expect Revance Therapeutics' stock price to reach $38.50 in the next twelve months. This suggests a possible upside of 23.4% from the stock's current price.
View analysts' price targets for Revance Therapeutics or view top-rated stocks among Wall Street analysts.

7 employees have rated Revance Therapeutics CEO Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among Revance Therapeutics' employees.

Some companies that are related to Revance Therapeutics include Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), Biohaven Pharmaceutical (BHVN), Perrigo (PRGO), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), I-Mab (IMAB), Schrödinger (SDGR), Legend Biotech (LEGN) and Reata Pharmaceuticals (RETA).
View all of RVNC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Revance Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (6.21%), Alliancebernstein L.P. (4.70%), Palo Alto Investors LP (4.48%), Jennison Associates LLC (2.94%), Capital International Investors (2.17%) and Geode Capital Management LLC (1.57%).
View institutional ownership trends for Revance Therapeutics.

RVNC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Jennison Associates LLC, Rothschild & Co. Asset Management US Inc., Northern Trust Corp, State of Wisconsin Investment Board, Citigroup Inc., Ameriprise Financial Inc., and Sei Investments Co..
View insider buying and selling activity for Revance Therapeutics or view top insider-selling stocks.

RVNC stock was acquired by a variety of institutional investors in the last quarter, including HighTower Advisors LLC, Palo Alto Investors LP, Capital International Investors, Bamco Inc. NY, Alliancebernstein L.P., Point72 Asset Management L.P., Geode Capital Management LLC, and Principal Financial Group Inc..
View insider buying and selling activity for Revance Therapeutics or or view top insider-buying stocks.

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RVNC stock can currently be purchased for approximately $31.21.

Revance Therapeutics has a market capitalization of $2.23 billion and generates $15.32 million in revenue each year. The biopharmaceutical company earns $-282,090,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis.

Revance Therapeutics employs 470 workers across the globe.

The official website for Revance Therapeutics is www.revance.com.

Revance Therapeutics is headquartered at 7555 GATEWAY BLVD., NEWARK CA, 94560.

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]